Teladoc (TDOC) AI Stock Analysis

Compare

11,945 Followers

Top Page

Teladoc

(NYSE:TDOC)

Rating:48Neutral

Price Target:―

Teladoc's stock score reflects a mix of financial and operational challenges, including revenue fluctuations and negative profitability metrics, countered by strengths in cash flow and strategic acquisitions. Despite potential for growth in certain segments, bearish technical indicators and valuation concerns weigh heavily on the overall assessment.

Positive Factors

Acquisition and Market Strategy

The acquisition of UpLift provides a solid pathway for in-network coverage in the BetterHelp segment, potentially offering affordability in an uncertain economic climate.

Financial Performance

Consolidated revenue and adjusted EBITDA both exceeded analyst and consensus estimates, with notable outperformance in the Integrated Care segment.

Membership Growth

Integrated Care membership grew nicely, up 12% to over 102.5MM members, representing potential cross-and upsell opportunities.

Negative Factors

Contract Loss Impact

Teladoc expects chronic care enrollment in the second quarter to decline sequentially due to a previously discussed contract loss.

Enrollment Decline

Livongo MAUs in April declined 17.5% year over year, continuing mid-teens percentage point declines over the last 12 months.

Revenue Decline

Average revenue per US Integrated Care Member fell 8.6% sequentially and 8.0% year-over-year, which could impact overall revenue growth.

Teladoc (TDOC) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$1.25B

Dividend YieldN/A

Average Volume (3M)4.99M

Price to Earnings (P/E)―

Beta (1Y)1.35

Revenue Growth-2.54%

EPS Growth-322.03%

CountryUS

Employees4,620

SectorHealthcare

Sector Strength41

IndustryMedical - Healthcare Information Services

Share Statistics

EPS (TTM)-0.53

Shares Outstanding175,434,770

10 Day Avg. Volume4,465,179

30 Day Avg. Volume4,994,340

Financial Highlights & Ratios

PEG Ratio1.80

Price to Book (P/B)0.87

Price to Sales (P/S)0.00

P/FCF Ratio5.96

Enterprise Value/Market Cap1.31

Enterprise Value/Revenue0.16

Enterprise Value/Gross Profit0.96

Enterprise Value/Ebitda-0.67

Forecast

1Y Price Target

$8.46

Price Target Upside22.08% Upside

Rating ConsensusHold

Number of Analyst Covering17

Teladoc Business Overview & Revenue Model

Company DescriptionTeladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.

How the Company Makes MoneyTeladoc generates revenue through a combination of subscription fees and visit fees. Subscription fees are primarily derived from contracts with employers, health plans, and insurance providers, who pay Teladoc to offer its services to their members or employees. These contracts are typically based on a per-member-per-month fee structure. Additionally, Teladoc earns visit fees each time a member uses its services for a medical consultation. The company also benefits from strategic partnerships with healthcare providers and insurers, which expand its reach and increase its client base. Other revenue streams include licensing its technology platform to other healthcare providers and offering specialty services that cater to specific medical needs.

Teladoc Key Performance Indicators (KPIs)

Any

US Integrated Care Members

US Integrated Care Members
Tracks the number of members using Teladoc's integrated care services in the US, indicating the company's reach and penetration in the domestic healthcare market.

Chart InsightsTeladoc's US Integrated Care Members have shown consistent growth, reaching over 102 million by Q1 2025. This growth aligns with the company's strategic focus on member engagement and international expansion, as highlighted in their earnings call. Despite challenges in other segments, such as BetterHelp, the Integrated Care segment remains a stable growth driver, supported by increased visit volumes and successful international partnerships. However, the anticipated flat to modest revenue growth in this segment suggests potential saturation or competitive pressures that investors should monitor.

Data provided by:

Main Street Data

Teladoc Earnings Call Summary

Earnings Call Date:Apr 30, 2025

(Q1-2025)

% Change Since: -3.62%|

Next Earnings Date:Jul 29, 2025

Earnings Call Sentiment Neutral

The earnings call presented a mix of positive strategic developments such as the acquisition of UpLift, growth in the Integrated Care segment, and international success, but these were offset by financial challenges, including revenue decline, net losses, and macroeconomic concerns. The sentiment is balanced, reflecting both opportunities and challenges.

Q1-2025 Updates

Positive Updates

Acquisition of UpLift

Teladoc Health announced the acquisition of UpLift, a virtual mental health company, to enhance its BetterHelp segment. UpLift is an in-network provider to health plans covering over 100 million lives, which aligns with Teladoc's strategic priorities.

Integrated Care Segment Growth

The Integrated Care segment saw revenue of $389.5 million, a 3.3% increase over the prior year, driven by U.S. virtual visit volume increase of 7% and chronic care enrollment growth of 3%.

International Business Success

Teladoc's international business in the Integrated Care segment grew with revenue increasing in the mid-teens on a constant currency basis.

Recognition for Trustworthiness

Teladoc was named to Newsweek's Most Trustworthy Companies in America for 2025 and ranked number one in the healthcare and life sciences industry.

Negative Updates

Revenue Decline

First quarter consolidated revenue was $629.4 million, down 3% year-over-year. BetterHelp segment revenue decreased by 11% compared to the prior year.

Net Loss Per Share

Consolidated net loss per share was $0.53, compared to a net loss per share of $0.49 in the first quarter of 2024, including a non-cash goodwill impairment charge.

Challenges in BetterHelp Segment

BetterHelp's adjusted EBITDA margin decreased from 5.7% to 3.2%, and average paying users declined slightly. There were increased member churn rates noted.

Macroeconomic and Tariff Concerns

The broader economic environment and potential $5 million to $10 million tariff impact pose challenges, particularly with the fluidity of the situation.

Company Guidance

During the Teladoc Health First Quarter 2025 Earnings Call, significant guidance was provided concerning financial performance and strategic initiatives. The company reported consolidated revenue of $629.4 million, with adjusted EBITDA of $58.1 million, both at the higher end of guidance ranges. The BetterHelp segment saw a revenue of $239.9 million and an adjusted EBITDA margin of 3.2%. For full-year 2025, Teladoc expects revenue between $2.47 billion and $2.58 billion, with an adjusted EBITDA range of $263 million to $304 million. The recent acquisition of UpLift is anticipated to contribute approximately $10 million in incremental revenue in 2025, with potential increased member durations and conversion rates due to benefits coverage. The company is also focusing on technology improvements and international expansion to drive growth. Despite uncertainties in the macroeconomic environment, Teladoc emphasized its strategic priorities to expand access to virtual mental health services and leverage its scale in integrated care and BetterHelp segments.

Teladoc Financial Statement Overview

Summary

Teladoc faces challenges with fluctuating revenue growth and ongoing losses reflected in negative net profit margins. However, stable gross profit margins and positive free cash flow indicate some financial strengths and improvement potential.

Income Statement

Neutral

Teladoc has shown fluctuating revenue growth, with a decline from 2023 to the TTM period. The gross profit margin is stable at around 66-67%, but the net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

Neutral

The debt-to-equity ratio is relatively high, suggesting considerable leverage, but the equity ratio demonstrates a stable equity base. The ROE remains negative due to continuous net losses, which indicates profitability concerns.

Cash Flow

Neutral

Free cash flow has been positive in the TTM period, showing signs of improvement. The operating cash flow to net income ratio is favorable, suggesting a good cash conversion from operations despite negative net income.

TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
2.55B	2.57B	2.60B	2.41B	2.03B	1.09B
	Gross Profit
1.70B	1.82B	1.84B	1.66B	1.38B	703.13M
	EBIT
-262.42M	-1.02B	-248.55M	13.20B	-238.99M	-418.19M
	EBITDA
-734.57M	-587.01M	154.00M	-13.38B	-84.67M	-438.01M
	Net Income Common Stockholders
-1.01B	-1.00B	-220.37M	-13.66B	-428.79M	-485.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.19B	1.30B	1.12B	918.18M	896.02M	786.57M
	Total Assets
3.44B	3.52B	4.39B	4.35B	17.73B	17.76B
	Total Debt
1.59B	1.58B	1.59B	1.57B	1.27B	1.47B
	Net Debt
393.44M	286.29M	468.60M	655.15M	373.96M	731.97M
	Total Liabilities
2.02B	2.03B	2.07B	2.04B	1.69B	1.87B
	Stockholders Equity
1.43B	1.49B	2.33B	2.31B	16.05B	15.88B
Cash Flow		Free Cash Flow
209.41M	282.89M	193.67M	16.53M	130.06M	-79.55M
	Operating Cash Flow
300.68M	293.68M	350.02M	189.29M	193.99M	-53.51M
	Investing Cash Flow
-211.81M	-124.05M	-156.35M	-167.74M	-72.98M	-590.98M
	Financing Cash Flow
7.33M	8.31M	10.85M	6.50M	40.95M	859.14M

Teladoc Technical Analysis

Technical Analysis Sentiment

Negative

Last Price6.93

Price Trends

50DMA

7.25

Negative

100DMA

8.78

Negative

200DMA

8.95

Negative

Market Momentum

MACD

-0.11

Negative

RSI

44.58

Neutral

STOCH

52.69

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Negative. The current price of 6.93 is below the 20-day moving average (MA) of 7.13, below the 50-day MA of 7.25, and below the 200-day MA of 8.95, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 44.58 is Neutral, neither overbought nor oversold. The STOCH value of 52.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TDOC.

Teladoc Risk Analysis

Teladoc disclosed 57 risk factors in its most recent earnings report. Teladoc reported the most risks in the “Ability to Sell” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 1 New Risks

In the U.S., a number of states have introduced healthcare transaction notification requirements which may impede our ability to grow through mergers, acquisitions, consolidations, and other transactions. Q4, 2024

Teladoc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	76 Outperform	$1.61B	15.25	11.19%	2.34%	19.16%	31.92%
PHR	58 Neutral	$1.53B	―	-15.97%	―	16.29%	66.01%
SDGR	56 Neutral	$1.68B	―	-43.33%	―	22.29%	-32.89%
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
TDOC	48 Neutral	$1.25B	―	-54.49%	―	-2.54%	-322.03%
ARQT	47 Neutral	$1.58B	―	-70.58%	―	100.03%	64.22%
ELVN	36 Underperform	$1.09B	―	-31.30%	―	―	12.85%

* Healthcare Sector Average

Performance Comparison

TDOC

Teladoc

6.93

-3.71

-34.87%

NHC

National Healthcare

105.44

4.59

4.55%

PHR

Phreesia

25.78

6.28

32.21%

ARQT

Arcutis Biotherapeutics

13.51

6.27

86.60%

SDGR

Schrodinger

23.84

2.10

9.66%

ELVN

Enliven Therapeutics

21.37

0.43

2.05%

Teladoc Corporate Events

Shareholder MeetingsBusiness Operations and Strategy

Teladoc Approves Key Proposals at Annual Meeting

Neutral

May 23, 2025

On May 22, 2025, Teladoc Health, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. Notably, the stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6,850,000. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed. These decisions are expected to impact the company’s strategic direction and operational governance.

The most recent analyst rating on (TDOC) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.